Brief: Epigenomics announces recent payment decision by CMS
21/11/2017 21:35
Nov 21 (Reuters) - Epigenomics AG ECXn.DE
* Epigenomics AG announces recent payment decision by CMS
* Epigenomics - CMS has changed pricing determination for
Epi
proColon(R), only fda-approved blood-based test for colorectal
cancer (CRC) screening
* Epigenomics - CMS agreed original "crosswalk"
determination was
not appropriate and reimbursement for Epi proColon should be
determined by "gapfilling"
Source text for Eikon: ID:nEQ3VC87Na
Further company coverage: ECXn.DE
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns